Skip to search formSkip to main contentSkip to account menu

PF 03084014

Known as: PF-03084014, PF03084014 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines
Multiple myeloma (MM) is a plasma cell malignancy characterized by clonal proliferation of plasma cells within the bone marrow. B… 
2018
2018
Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
As a multi-kinase inhibitor, sorafenib is beneficial in around 30% of hepatocellular carcinoma (HCC) patients; however, HCC… 
2018
2018
Combined Erlotinib and PF‐03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is characterized by high mortality and low survival rates. As an epidermal growth… 
2016
2016
Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.
11028Background: Desmoids are rare, locally invasive, slow growing soft tissue tumors that are either sporadic or associated with… 
2015
2015
Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC).
1068 Background: Gamma secretase is a key component of the Notch signaling pathway, which is involved in cancer cell biology and… 
2014
2014
New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
A phase I trial of PF-03084014, an oral reversible γ-secretase inhibitor, in solid tumor malignancies shows drug tolerability in… 
2014
2014
Initial testing (stage 1) of the notch inhibitor PF‐03084014, by the pediatric preclinical testing program
PF‐03084014, a γ‐secretase inhibitor, was tested against the PPTP in vitro cell line panel (1.0 nM to 10 μM) and against the in… 
2014
2014
Endocrine therapy resistance and epithelial to mesenchymal transition are driven by Nicastrin and Notch4 cooperation in MCF7 breast cancer cells.
Endocrine therapy resistant (ETR) tumors often display mesenchymal features, associated with aggressive and enhanced motility… 
2012
2012
ALDH+ tumor‐initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ‐secretase inhibitor and irinotecan in colorectal cancer
2011
2011
A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors.
3100 Background: Aberrant Notch signaling is implicated in tumor genesis. Gamma secretase plays a key role in Notch-dependent… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)